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ABSTRACT 
The transcription factor ATF5 protects cortical neurons from toxicity induced by 
prostaglandin J2. 
 
by 
Fanny Cheung 
 
Advisor: Dr. Patricia Rockwell 
 
 Mitochondrial dysfunction has been recognized to play a central role in the pathogenesis 
of neurodegenerative disorders, including Parkinson’s and Alzheimer’s disease. Transcription 
factor ATF5 has been shown to mediate an endogenous stress pathway known as the UPRmt, a 
prosurvival mechanism amidst malfunctioning mitochondria. However, the ATF5/UPRmt 
protective pathway associated with mitochondrial impairment in neurons remains to be 
elucidated. To decipher the regulatory mechanisms involved with mediating neuroprotection, the 
effect of ATF5 was examined on the mitochondrial dysfunction induced by the proinflammatory 
prostaglandin PGJ2 in rat cortical neurons. ATF5 overexpression protected the effects induced 
by PGJ2 by attenuating HO-1 induction, Caspase-3 cleavage, cell loss, ROS production, and a 
collapse of the mitochondrial membrane potential ΔΨ
m
. With the exception of Capsase-3 
activation, silencing ATF5 escalated PGJ2 induced toxicity thereby attenuating the prosurvival 
effects of ATF5 overexpression. Detecting protein expression only in the presence of PGJ2 
treatment along with constant levels of ATF5 transcript, whether PGJ2 stress is present or not, 
proposes PGJ2 stress induces protein expression by stabilizing ATF5 transcript for translation. 
PGJ2 stress elicited ATF5 trafficking between the mitochondria and nucleus suggests organelle 
	 v	
partitioning accompanies the protection promoted by ATF5. Inhibition of the MEK/ERK 
signaling pathway with the selective inhibitor U0126 revealed yet another level of anti-apoptotic 
regulation by ATF5. A blockade of ERK activation prevented the protection by ATF5 by 
increasing the loss in cell viability induced by PGJ2. These findings suggest that ERK activation 
plays a role in AFT5 mediated protection in cortical neurons. In assessing mitochondrial function 
and glycolysis respiration, our findings suggest ATF5 protection against PGJ2 toxicity involves 
modulating mitochondrial functions. Reduction of cellular respiration demand by ATF5 
observed in PGJ2 stressed neurons may relieve damaged mitochondria from the pressure of 
maintaining unsustainable energy production levels. Glycolysis contribution towards cellular 
energy demands remained the same regardless of ATF5 overexpression or silencing supporting 
the ability of ATF5 to alter overall cellular expenditure requirements through mitochondrial 
respiration. Mediating ATF5 protection by improving mitochondrial efficacy provides a possible 
pathway towards re-establishing homeostasis and recovery of the mitochondria.  
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1.1.  Introduction 
 
Mitochondrial dysfunction has been recognized to play an important role in 
neurodegenerative disorders, including Parkinson’s and Alzheimer’s disease. The human brain 
accounts for approximately 20% of the body’s energy demand, more energy than any other organ 
(Rolfe 1997). Essential for cellular function, mitochondria are tiny powerhouses with roles in 
ATP production, calcium homeostasis, and apoptotic signaling (Celardo 2014). As high energy-
using cells, neurons rely on the mitochondria for their supply of energy (Weissman 2007). 
Therefore, understanding mitochondrial dysfunction in stressed neurons and strategies for 
recovery can provide novel insights towards therapeutic treatments for neurodegenerative 
disorders.  
 Chronic neuroinflammation is implicated in the pathogenesis of neurodegenerative 
disorders including Parkinson (PD), Alzheimer (AD), and Huntington diseases. The cascade of 
events leading to neuronal degeneration may possibly be triggered by a self-perpetuating cycle of 
inflammation processes that is activated upon injury to the CNS (Hirsch 2009). High levels of 
prostaglandins are released by the microglia and astrocytes that are activated by inflammatory 
mechanisms. Cyclooxygenases (COX-1 and COX-2) are key enzymes that contribute to the 
biosynthesis of prostaglandins in inflammation (Figueiredo-Pereira 2015). Evoked by numerous 
extrinsic and intrinsic stimuli, the cyclooxygenase pathway converts arachidonic acid to 
bioactive prostanoids. Transitioning from acute to chronic inflammation is a poorly understood 
mechanism. Animal studies have provided evidence that prostaglandins not only mediate acute 
inflammation but also function in the transition to and maintenance of chronic inflammation 
(Pierre 2009; Shiver 2014). Derived from PDG2, the highly toxic endogenous J2 prostanglandin 
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levels are significantly increased when traumatic brain injuries are encountered. PGJ2 released 
from microglia and astrocytes perpetuate its synthesis via an upregulation of COX-2 to activate a 
positive feed-back loop of neuroinflammation (Figure 1). The 
ubiquitin-proteasome pathway (UPP) and mitochondrial 
function are targets of J2 prostaglandins and impairment of 
these mechanisms play key roles in the neurodegenerative 
process. It has been demonstrated that J2 prostaglandins 
inhibit the proteasome by (1) impairing the 26S proteasome 
(2) inhibiting de-ubiquitinating enzymes (DUBs) and (3) 
covalently modifying specific active site cysteines on UPP 
components. Moreover, the inhibition of mitochondrial 
function by J2 prostaglandins leads to oxidative stress and 
apoptosis through (1) the inhibition of complex I (2) a 
decrease in the mitochondrial membrane potential (MMP) (3) 
ROS overproduction and (4) a blockade of mitochondrial 
division (Figure 2). Detecting stress-induced heme 
oxygenase-1 (HO-1) enzyme indicates the presence of 
oxidative stress (Keyse & Tyrrell 1989). In the event of 
proapoptotic stimuli leading to apoptosis, activation of executioner Caspase-3 by cleavage 
follows after cytochrome c releases from the mitochondrial intermembrane into the cytosol to 
combine with Apaf-1 and Caspase-9 (Li 1997). Impairment of both the mitochondria and UPP 
are hallmarks of neurodegenerative disorders. As a model, utilizing PGJ2 to induce 
neuroinflammation mimics various key features, such as mitochondrial and UPP dysfunction  
FIGURE 1 | Potential 
mechanism by which J2 
prostaglandins promote 
neurodegenration. During 
neuroinflammation PGJ2 are 
released from activated 
microglia and astrocytes. 
PGJ2 increase the levels of 
COX-2, thus activating a 
positive feedback loop that 
could mediate the transition 
from acute to chronic 
inflammation. (Figueiredo-
Pereira et al 2015)	
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implicated with neurodegenerative diseases.  
 Mitochondria are critical regulators of cell survival and death, such that their dysfunction 
has been suggested to play a central role 
in the pathogenesis of neurodegeneration. 
Maintaining mitochondrial protein 
homeostasis, consisting of proper folding 
and assembly of newly translated 
polypeptides along with efficient 
trafficking and turnover of those proteins 
that fail to fold correctly, allows for 
proper function and biogenesis (Haynes 
2013; Lionaki 2015). Thirteen of the 
components of the electron transport 
chain (ETC) and the tRNAs and rRNAs 
required for their synthesis are encoded 
by mitochondrial DNA. Therefore, a 
majority of the 1100 proteins that 
comprises the mitochondrial proteome is 
encoded by nuclear genes where they are 
translated in the cytosol and then 
imported into each organelle. Nucleus-
encoded proteins synthesized in the 
cytosol that are targeted to the 
FIGURE 2 | J2prostaglandins target the ubiquitin 
proteasome pathway (UPP) and mitochondria. J2 
prostaglandins affect the UPP by: (1) impairing the 
26S proteasome by inducing oxidation of proteasome 
subunits, or promoting its disassembly,(2) inhibiting 
de-ubiquitinating enzymes (DUBs),and (3) covalently 
modifying specific active site cysteines on UPP 
components such as E1 activating enzymes, E2 
conjugating enzymes, and some E3ligases. J2 
prostaglandins can also inhibit mitochondrial function 
by: (1) inhibiting NADH-ubiquinone reductase in 
complex I, (2) reducing membrane potential, (3 ) 
blocking fission,and (4) inducing the generation of 
reactive oxygen species (ROS) and apoptosis. 
(Figueiredo-Pereira et al 2015)	
	 5	
mitochondria typically have an N-terminal mitochondrial targeting sequence (MTS) (Jovaisaite 
2014; Haynes 2010). An endogenous stress pathway known as the UPRmt, that promotes survival 
during mitochondrial dysfunction, has been identified in C. elegans (Nargund 2012). Under 
conditions of mitochondrial stress, cell monitoring or protein import efficiency by the 
mitochondria signals accumulation. This event leads to induction of UPRmt and promotes 
mitochondrial protective genes to re-establish protein homeostasis. Evidence indicates the 
requirement for Activating Transcription Factor associated with Stress-1 (ATFS-1) in UPRmt 
induction. ATFS-1 is believed to function as a sensor of mitochondrial import efficiency by 
possessing the ability to localize to both the mitochondria and nucleus due to an N-terminal MTS 
region and a nuclear localization sequence (NLS) in the leucine-zipper domain, respectively. 
When ATFS-1 is directed to the mitochondria in healthy cells it undergoes rapid degeneration. 
However, a reduction in mitochondria import efficiency during mitochondrial stress allows 
AFTS-1 to accumulate in the cytoplasm. Because ATFS-1 also has a nuclear localization 
sequence (NLS), it then traffics to the nucleus where it mediates a protective transcriptional 
program specific for restoring mitochondrial homeostasis. The trafficking of ATFS-1 either to 
the mitochondria in non-stress cells or to the nucleus to activate the protective UPRmt under 
mitochondrial stress conditions provides ATFS-1/UPRmt pathway as a mechanism for cells to 
monitor mitochondrial homeostasis. ATF5, the mammalian ortholog of AFTS-1, has been 
revealed by studies to be highly expressed as a anti-apoptotic protein in a variety of human 
cancer cell lines and to function in suppressing the differentiation of neuroprogenitor cells into 
neurons or glia (Greene 2009). In addition, studies have demonstrated that adult neurons of a 
mouse model of status epilepticus express ATF5 and that they increase its levels upon 
endoplasmic reticulum stress as a pro-survival mechanism, suggesting a neuroprotective role for 
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ATF5 (Torres-Peraza 2013; Hetz 2013). Evidence also revealed a decrease and sequestering of 
the neuroprotective transcription factor ATF5 in Huntington’s disease (Hernandez 2017). The 5’-
untranslated region regulates the mRNA stability of stress-response transcription factor ATF5 
(Hatano 2013). Phosphorylation of eIF2 has been shown to direct ATF5 translation in 
environmental stress conditions by a mechanism delaying translation reinitiation in the 5’-
untranslated region (Zhou 2008). The binding of HSP70 contributes to the stability of ATF5 by 
blocking protein degradation to promote survival (Li 2011). However, it is unknown whether this 
protection is linked to mitochondrial impairment in neurons through UPRmt.  
 The objective of this study is to evaluate the impact ATF5 overexpression will have on 
mitochondrial dysfunction induced by chronic neuroinflammation. As highly neurotoxic 
endogenous products of inflammation, J2 prostaglandins (products of cyclooxygenases) lead to 
oxidative stress and apoptosis by inhibiting mitochondrial function. Utilizing an established in 
vitro model of neuroinflammation induced by prostaglandin J2 (PGJ2) to activate the 
ATF5/UPRmt pathway we demonstrated ATF5 to be a protective transcription factor against 
PGJ2 induced toxicity in rat cortical neurons.  
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1.2.  RESULTS 
 
1.2.1.  Cell cytotoxicity induced by PGJ2 
ATFS-1 activates the protective UPRmt pathway during mitochondrial stress in C. elegans 
(Nargund 2012). To study ATF5, the mammalian ortholog of AFTS-1, under conditions of cell 
cytotoxicity, proteins extracted from PGJ2 treated rat cortical neurons were analyzed by western 
blotting. Cellular damage was assessed by probing for the presence of HO-1, a biomarker of 
oxidative stress. Additionally, cleaved Caspase-3 levels were examined to ascertain execution 
activities that lead to apoptosis. Significant increases of cleaved Caspase-3 and HO-1 levels were 
observed with PGJ2 treatment suggesting oxidative stress and apoptosis are induced under the 
stress of PGJ2 (Figure 3A compare lane 1 and 2). Results also revealed an upregulation of ATF5 
when cortical neurons were treated with PGJ2 (Figure 3A, compare lane 1 and 2). Performing an 
MTS assay to evaluate cell viability showed a cell loss of approximately 20% with PGJ2 
treatment (Figure 3E). The loss of cell viability further implicates PGJ2 induces cytotoxicity 
demonstrated by the increase in both oxidative stress and caspase activation.  	
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Figure 3. Cell cytotoxicity induced by PGJ2 in primary cortical neurons.  
(A) E18 cortical neurons were incubated for 16hrs in DMEM and treated with and without 
PGJ2 (10µM) for 16 h. Lysates were analyzed by western blotting probing with antibodies 
for Caspase-3, HO-1, and ATF5. Actin was probed as a loading control. (B,C,D) Blots 
were quantified using ImageJ. ****(P<0.0001) indicates a significant difference between 
PGJ2 vs. control in DMEM for Caspase-3, HO-1, and ATF5. (E) Cell viability was 
determined using an MTS assay as described in the Materials and Methods section. 
Results represent the percent cell viability relative to the vehicle control + S.E.M. 
****(P<0.0001) indicates a significant difference between PGJ2 vs. control. 	
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1.2.2.  ATF5 overexpression protects against PGJ2 toxicity 
An increase in ATF5 is associated with PGJ2 induced toxicity (Figure 6). To investigate 
the role of ATF5 under a PGJ2 stressed environment cortical neurons were transfected with an 
ATF5 construct to promote overexpression. Western blot analyses of extracted proteins probing 
for ATF5 indicated an increase in ATF5 protein levels when treated with PGJ2 (Figure 4A, 
compare lane 2 and 4). Elevated ATF5 levels with PGJ2 treatment alone manifested under 
induction conditions. Conversely, ATF5 overexpression diminished HO-1 and Caspase-3 
activation identified in PGJ2 treated neurons (Figure 4A, compare lane 2 and 4). The lowering of 
HO-1 and cleaved Caspase-3 levels suggest a protective role for ATF5. According to MTS 
assays, overexpressing ATF5 in PGJ2 treated cells improved cell viability by approximately 10% 
demonstrating its ability to insulate against PGJ2 toxicity (Figure 4E).   
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	 Figure 4. ATF5 overexpression protects 
against PGJ2 toxicity.  
(A) E18 cortical neurons transfected with an ATF5 
construct using a magnetofection technique as 
described in the Materials and Methods section 
were incubated for 16hrs in DMEM and treated 
with and without PGJ2 (10µM) for 16 h. Lysates 
were analyzed by western blotting probing with 
antibodies for Caspase-3, HO-1, and ATF5. Actin 
was probed as a loading control. (B,C,D) Blots 
were quantified using ImageJ. ****P<0.0001 for 
comparisons to Control in DMEM for Caspase-3, 
HO-1, and ATF5. ####P<0.0001 for comparisons 
to ATF5/PGJ2 in DMEM for Caspase-3, HO-1, 
and ATF5. ++++P<0.0001 for comparisons to 
ATF5/Control in DMEM for Caspase-3, HO-1, and 
ATF5.  (E) Cell viability was determined using an 
MTS assay as described in the Materials and 
Methods section. Results represent the percent 
cell viability relative to the vehicle control + S.E.M. 
****P<0.0001, **(P<0.01) for comparisons to 
Control. ####P<0.0001 for comparisons to 
ATF5/PGJ2. +(P<0.05) for	 comparisons	 to	ATF5/Control. 	
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 1.2.3.  ATF5 traffics to both the mitochondria and nucleus 
Evidence has established the trafficking of ATFS-1 to the nucleus under mitochondrial 
stress conditions activates the protective UPRmt (Nargund 2012). Identifying the nuclear 
localization sequence (NLS) in ATF5 along with its ability to regulate mitochondrial chaperone 
HSP60 and mtHSP70 suggests ATF5 mimics the ATFS-1 mediated UPRmt in C. elegans (Fiorese 
2016). To explore a similar mechanism possibly mediating ATF5 protection in cortical neurons 
cell fractionations of PGJ2 treated cells were utilized to determine the localization of ATF5. 
Analyzing proteins extracted from each fraction by western blotting revealed increased levels of 
ATF5 in the nuclear fractions (Figure 5A, compare lanes 1,3,5 to 2,4,6) when treated with PGJ2. 
Examining neurons transfected with ATF5 in combination with PGJ2 treatment showed elevated 
amounts of ATF5 in both the mitochondrial and nuclear fractions (Figure 5A, compare lanes 
7,9,11 to 8,10,12). Similar to results observed in Fig 4, a decrease in cleaved Caspase-3 levels in 
the cytosolic fractions of PGJ2 treated neurons transfected with ATF5 (Figure 5A, compare lanes 
2 and 8) suggest the drop in initiating the caspase cascade leads to lower occurrences of 
apoptosis. Localization of ATF5 in PGJ2 stressed cortical neurons to both the mitochondria and 
nucleus combined with an increase in cell viability when ATF5 is overexpressed proposes 
trafficking induced by PGJ2 stress conditions promote ATF5-mediated protection.  		
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Figure 5. ATF5 traffics to both the mitochondria and nucleus. (A) E18 cortical neurons transfected 
with an ATF5 construct using a magnetofection technique as described in the Materials and Methods 
section were incubated for 16hrs in DMEM and treated with and without PGJ2 (10µM) for 16 h.  
Lysates cell fractionated as described in the Materials and Methods section were analyzed by western 
blotting probing with antibodies for Caspase-3 and ATF5. Cytochrome C was probed as a fractionation 
control. Tubulin was probed as a loading control. (B,C) Blots were quantified using ImageJ. ##P<0.01 
for comparisons to Mit/control in DMEM for ATF5. +P=0.005, +++P<0.001 for comparisons to 
Nuc/control in DMEM for ATF5. ****P<0.0001 for comparisons to Cyt/control in DMEM for Caspase3.  
B C 
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1.2.4.  PGJ2 stress induces ATF5 mRNA expression 
 Elevated ATF5 protein levels can be attributed to the upregulation	of	endogenous	ATF5	and/or	 expression	 of	 the	 ATF5	 construct.	 Examining expression levels of ATF5 by 
quantitative RT PCR will elucidate the source of the increase.	 After confirming the ATF5 
construct successfully increased gene expression (data not shown), focus was directed towards 
determining whether PGJ2 induces ATF5 at the transcriptional level independent of the ATF5 
construct.	 Analyzing RNA extracted from cortical neurons treated with and without PGJ2 
(10μM) by RT qPCR revealed similar steady rates of ATF5 expression levels for both Primer 1 
(Figure 6A, compare Control vs PGJ2) and Primer 2 (Figure 6B, compare Control vs PGJ2). 
Negligible differences between PGJ2 treated and non-stressed neurons demonstrate a constant 
transcription of ATF5 mRNA independent of PGJ2 stress. Amino acid limitation has been shown 
to induce ATF5 mRNA expression in HeLaS3 cells partly as a result of increasing the half-life of 
ATF5 mRNA transcript (Watatani 2007). Identifying uORFs in the 5’-UTRs of mRNA splice 
variants ATF5a and ATF5b revealed 5’-UTRa regulates mRNA stability via NMD in response 
to stress (Hatano 2013). Additionally, studies have illustrated ATF5 degradation by the 
ubiquitin-proteasome pathway (UPP) is prevented by cadmium treatment and DNA-damaging 
agent cisplatin (Wei 2008; Uekusa 2009). Observing an increase in ATF5 protein levels under 
PGJ2 treatment conditions suggest PGJ2 stress induces the stabilization of ATF5 mRNA and 
together with its inhibition of the proteasome (Wang 2006) obstructs the degradation of ATF5, 
thus enabling gene expression.  		
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Figure 6. PGJ2 stress induces ATF5 mRNA expression. (A) Quantitative RT PCR was 
performed on RNA extracted from E18 cortical neurons transfected with an ATF5 construct 
using a magnetofection technique as described in the Materials and Methods section after 
incubation of 16hrs in DMEM and treated with and without PGJ2 (10µM) for 16 h. Results 
generated from Primer 1 and primer 2 were quantified using ImageJ.  	
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1.2.5.  ATF5 silencing exacerbates PGJ2 toxicity 
 Investigating the effects of silencing ATF5 in PGJ2 stressed cortical neurons by siRNA 
provides additional evidence to support the protective role of ATF5 (Figure 4). Western blot 
analyses of extracted proteins probing for ATF5 indicated the increase in ATF5 under PGJ2 
stress conditions (Figure 7A, compare lane 1 and 3) diminishes when ATF5 is silenced (Figure 
7A, compare lane 3 and 4). Additionally, a higher oxidative stress presence, demonstrated by a 
rise in HO-1, was observed in ATF5 suppressed neurons treated within PGJ2 (Figure 7A, 
compare lane 3 and 4). However, cleaved Caspase-3 levels did not exhibit a significant change 
when ATF5 is silenced under PGJ2 stressed conditions (Figure 7A, compare lane 3 and 4). 
Findings from MTS assays showing an additional drop of approximately10-20% in cell viability 
(Figure 7E) coincide with the increase of oxidative stress and a decrease of ATF5 levels. To 
account for the increased loss in cell viability alternative forms of cell death pathways besides 
caspase-dependent apoptosis should be considered, such as caspase-independent cell death 
involving autophagy, necrosis, or MOMP-inducing stimuli (Tait and Green 2008). Together 
these results suggest silencing ATF5 attenuates protection against PGJ2 toxicity. 	
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Figure 7. ATF5 silencing exacerbates PGJ2 toxicity. (A) ATF5 silenced E18 cortical neurons using 
an siRNA technique described in the Materials and Methods section were incubated for 16hrs in 
DMEM and treated with and without PGJ2 (10µM) for 16 h. Lysates were analyzed by western blotting 
probing with antibodies for Caspase-3, HO-1, and ATF5. Actin was probed as a loading control. 
(B,C,D) Blots were quantified using ImageJ. ****P<0.0001, ***P<0.001 for comparisons to Control in 
DMEM for HO-1, ATF5, and Caspase-3. ***P<0.001 for comparisons to Control siRNA in DMEM for 
Caspase3.  ####P<0.0001 for comparisons to Control siRNA in DMEM for HO-1 and ATF5. 
++++(P<0.0001), +++P<0.001, +P<0.05 for comparisons to PGJ2 siRNA in DMEM for ATF5, HO-1, 
and Caspase-3. (E) Cell viability was determined using an MTS assay as described in the Materials 
and Methods section. Results represent the percent cell viability relative to the vehicle control + S.E.M. 
****P<0.0001, ***P<0.001 for comparisons to Control. #P<0.05 for comparisons to PGJ2.  	
A B 
D E 
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1.2.6.  Silencing ATF5 abrogates mitochondrial and nuclear trafficking 
To further substantiate the proposal that PGJ2 stress stabilization of ATF5 mRNA 
promotes trafficking cell fractionations of ATF5 silenced cortical neurons treated with and 
without PGJ2 were examined to identify the localization of ATF5. Probing each fraction for 
ATF5 by western blotting revealed augmented levels of ATF5 protein in the nuclear fractions 
treated with PGJ2 (Figure 8A, compare lanes 1,3,5 to 2,4,6) but the silencing of ATF5 eliminated 
those increases (Figure 8A, compare lanes 4,6 to 10,12). In contrast, cleaved Caspase-3 levels in 
cytosolic fractions remained high and are visibly present in the mitochondria of ATF5 silenced 
neurons that received PGJ2 treatment (Figure 8A, compare lanes 2,4 to 8,10). Progression 
towards apoptosis by the activation of the executioner caspase reflects the decrease observed in 
cell viability when ATF5 is silenced in PGJ2 stressed conditions (Figure 7). The loss of ATF5 
protein levels, in both the nuclear and mitochondrial fractions, resulting from siRNA targeted 
degradation inhibits ATF5 transcript stability preventing protection against PGJ2 toxicity.  
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Figure 8. Silencing ATF5 abrogates mitochondrial and nuclear trafficking in PGJ2 stressed 
cortical neurons. (A) ATF5 silenced E18 cortical neurons using an siRNA technique described in the 
Materials and Methods section were incubated for 16hrs in DMEM and treated with and without PGJ2 
(10µM) for 16 h. Lysates cell fractionated as described in the Materials and Methods section were 
analyzed by western blotting probing with antibodies for Caspase-3 and ATF5. Cytochrome C was 
probed as a fractionation control. Tubulin was probed as a loading control. (B,C) Blots were quantified 
using ImageJ. ****P<0.0001, *P<0.05 for comparisons to Cyt/control in DMEM for ATF5 and Caspase-
3. ####P<0.0001, #P<0.05 for comparisons to Mit/control in DMEM for ATF5 and Caspase-3. 
++++P<0.0001 for comparisons to Nuc/control in DMEM for ATF5.  		
B C 
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1.2.7.  Inhibition of ATF5 by siRNA reduces ATF5 expression levels	
Investigating expression levels under ATF5 repression allows exploration of siRNA 
effectiveness for ATF5. RNA extracted from cortical neurons with ATF5 silencing treated with 
and without PGJ2 (10μM) analyzed by RT qPCR showed a significant decrease in ATF5 
expression levels compared to those without siRNA for both Primer 1 (Figure 9A, compare 
Control vs Control siATF5 and PGJ2 vs PGJ2 siATF5) and Primer 2 (Figure 9B, compare 
Control vs Control siATF5 and PGJ2 vs PGJ2 siATF5). Demonstrating proficient suppression of 
ATF5 expression by siRNA establishes that siRNA diminished ATF5 protection against PGJ2 
stress, reflected in the exacerbation of PGJ2 toxicity (Figure 7) and abrogation of ATF5 
trafficking between the mitochondria and nucleus (Figure 8).  
 
 
 
 
 
 
 
 
 
Figure 9. Inhibition of ATF5 by siRNA reduces ATF5 expression levels. (A) Quantitative RT PCR 
was performed on RNA extracted from ATF5 silenced E18 cortical neurons using an siRNA technique 
described in the Materials and Methods section after incubation of 16hrs in DMEM and treated with 
and without PGJ2 (10µM) for 16 h. Results generated from Primer 1 and primer 2 were quantified 
using ImageJ. ****P<0.0001, **P<0.01, *P<0.05 for comparisons to Control in DMEM for ATF5 Primer 
1 and Primer 2. ++++P<0.0001, ++P<0.01, +P<0.05 for comparisons to PGJ2 in DMEM for ATF5 
Primer 1 and Primer 2.  	
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1.3.  Discussion 		 Accounting for approximately 20% of the body’s energy demand (Rolfe 1997), the 
human brain relies on the mitochondria as a major source of energy (Weissman 2007). 
Recognizing the central role mitochondrial dysfunction plays in the pathogenesis of 
neurodegeneration necessitates insight into understanding recovery from mitochondrial 
impairment. As a highly neurotoxic endogenous product of inflammation, J2 prostaglandins lead 
to oxidative stress and apoptosis by inhibiting mitochondrial function (Figueiredo-Pereira 2015). 
Utilizing an established in vitro model of neuroinflammation induced by PGJ2 permitted 
investigating ATF5, the mammalian ortholog of UPRmt activator ATFS-1, under conditions of 
mitochondrial dysfunction. Results from our study affirm that ATF5 protects against PGJ2 
induced toxicity in rat E18 primary cortical neurons. The upregulation of ATF5 protein 
expression ameliorates HO-1 induction, cleaved Caspase-3 activation, and cell loss invoked by 
PGJ2 stress (Figure 4). Additionally, exacerbating cell loss viability with the silencing of ATF5 
demonstrates the protection endogenous ATF5 provides against PGJ2 toxicity (Figure 7), 
whereby upregulation enhances this protection. Improvements to the 10% cell loss recovery with 
ATF5 upregulation can further illustrate the potency of ATF5 protection. This may be achievable 
by increasing PGJ2 stress with an increase in treatment concentration but for a shorter period of 
time or decreasing PGJ2 toxicity with a decrease in treatment concentration but increase 
exposure time to longer than 16 hrs.   
The protective ATFS-1/UPRmt pathway is identified in C. elegans as a mechanism for 
cells to monitor mitochondrial homeostasis (Nargund 2012). Predicted to contain both an N-
terminal mitochondrial targeting sequence (MTS) and a nuclear localization signal (Claros 
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1996), ATFS-1 possesses the ability to migrate to either the mitochondria or the nucleus. When 
directed to the mitochondria in healthy cells it undergoes rapid degeneration, while trafficking to 
the nucleus during mitochondrial stress activates the protective UPRmt (Nargund 2012). The 
association between the mitochondria and nucleus in UPRmt signaling is implicated for ATF5 in 
fractionation experiments showing ATF5 presence in the mitochondria whereas accumulation in 
the nucleus occurs only under PGJ2 stress conditions (Figure 5). This finding is further 
demonstrated by ATF5 overexpression where protein levels are increased in both the nucleus and 
mitochondria, suggesting UPRmt involvement. Apoptosis associated with mitochondrial 
dysfunction via the intrinsic pathway involves the release of cytochrome c into the cytosol (Tait 
2008). The lack of cytochrome c detection in the cytosol fractions (Figure 5) may simply be an 
antibody sensitivity issue. This can be resolved by using an alternative cytochrome c antibody 
with greater sensitivity in western blot analyses. Stress evoked induction of mitochondrial 
protective transcripts in an ATF5-dependent manner identifies ATF5 regulation of a UPRmt in 
mammalian cells, analogous to the response regulated by ATFS-1 in C.elegans (Fiorese 2016). 
Affiliating ATF5 with a UPRmt in cortical neurons presents the possibility that molecular 
chaperones are also activated to restore mitochondrial homeostasis.  
 ATF5 is a stress-response transcription factor regulated by the 5’-untranslated region 
stabilizing its mRNA (Hatano 2013). This ability to stabilize mRNA along with PGJ2 induced 
proteasome inhibition (Wang 2006) interfering with ATF5 degradation provides an explanation 
for the detection of ATF5 protein expression uniquely under PGJ2 stress conditions (Figure 3) 
even though transcript levels remained constant in the absence and presence of PGJ2 treatment 
(Figure 6). Furthermore, silencing ATF5 reduced mRNA in scenarios with and without PGJ2 
treatment (Figure 9), curtailing ATF5 protection against PGJ2 toxicity (Figure 7 and 8). 
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Collectively, these findings suggest that PGJ2 stress stabilizes ATF5 mRNA for translation into 
protein and prevents proteasome degradation of ATF5 allowing it to protect against PGJ2 
toxicity.  
 Translocations of active Caspase-3 from the cytosol to the mitochondria (Chandra 2003) 
evoked by Status Epilepticus in neuronal death suggest the maneuver facilitates apoptosis (Kim 
2018). A trafficking pattern of enhanced Caspase-3 activation in both the cytosol and 
mitochondria under ATF5 silencing and PGJ2 treatment (Figure 8) demonstrate a similar 
rationale applies to our scenario. The accompanying reduction in cell viability (Figure 7E) 
fortifies the reasoning that active Caspase-3 in the mitochondria contributes to the apoptotic 
process by possibly participating in the degrading of mitochondria proteins, activation of resident 
procaspases, and dismantling of the mitochondria.  
An in vitro model of mammalian cell death studying trophic factor-deprivation-induced 
death of rat sympathetic neurons implicates the mitochondrion as an important regulator of 
caspase-dependent and caspase-independent cell death (CICD) (Chang 2002). Findings speculate 
that cytochrome c release together with activation of caspases govern cell death (Putcha 1999; 
Deshmukh 1996). In the absence of caspase, extending the commitment to neuronal death 
beyond cytochrome c release ends at the point of mitochondrial depolarization (Deshmukh 
2000), while inhibition with permeability transition pore (PTP) inhibitor Cyclosporin A in 
sympathetic neurons reveals PTP opening is a critical event in CICD (Chang 2002). Therefore, it 
has been proposed that the consequences from damaging the mitochondria entail killing cells in 
two ways: one is quick and dependent on caspase activation whereas the other is slower, 
repercussions of a major dysregulation of mitochondrial functions (Ricci 2003). The additional 
loss in cell viability observed in ATF5 silenced neurons receiving PGJ2 treatment, where 
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Caspase-3 cleavage levels were not exacerbated but an escalation in HO-1 indicated oxidative 
stress (Figure 7), can potentially be explained by CICD. Mitochondria-derived ROS, where 
overproduction results in oxidative stress, have been suggested to orchestrate caspase-dependent 
and -independent neuronal deaths in sympathetic neurons (McManus 2014). CICD was 
accompanied by the loss of mitochondrial membrane potential and the generation of reactive 
oxygen species in mouse embryonic fibroblasts (MEFs) (May 2007). Further support was 
exhibited by the involvement of ROS in death ligand FasL-induced CICD and inflammatory 
responses in MEFs (Chen 2009). Human embryonic kidney epithelial cells (293T cells) also 
demonstrate caspase-independent cell death results from the progressive loss of mitochondria 
function, rather than the release of cytotoxic protein (Lartigue 2009). ROS production was 
revealed to be involved in inducing autophagy, a contributor to caspase-independent macrophage 
cell death (Xu-2006). Silencing ATF5 impedes protection against PGJ2 toxicity to create an 
environment of chronic oxidative stress (Figure 7D), allowing CICD to possibly develop.  
 Overall, our study demonstrates the neuroprotective role ATF5 plays against PGJ2 
induced toxicity in cortical neurons is mediated by transcript stabilization. Insight provided from 
our findings about mitochondrial impairment and strategies for recovery by overexpressing 
ATF5 may lead to the development of therapeutic treatments for neurodegenerative disorders. 
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CHAPTER II 
 
ERK pathway regulates ATF5 protection against PGJ2 toxicity in 
primary cortical neurons 
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2.1.  Introduction 
 
 The extracellular signal-regulated kinase (ERK) signaling cascade is involved in a variety 
of cellular functions including migration, differentiation, proliferation and death. As a member of 
the mitogen-activated protein kinase (MAPK) family, ERK is expressed as a protein kinase 
intracellular signaling molecule that participates in a communication cascade from the cell 
membrane to the nucleus when activated by phosphorylation. ERK illustrates its role in cell 
survival and death by regulating neuronal apoptosis (Li 2014). Maintaining survival proteins at 
high levels via the ERK-dependent pathway has been demonstrated in chick retinal neurons 
(Desire 2000). The ERK survival pathway is shown to regulate apoptosis in hippocampal 
neurons (Perkins 2003).    
A chain reaction of caspase activation is associated with the two principal pathways that 
lead to apoptosis (Cory 2002). The cell-extrinsic death pathway involves death receptors while 
the Bcl-2 protein family regulates the intracellular stress induced cell-intrinsic death pathway 
(Cory 2002). Consisting of anti-apoptotic proteins and two pro-apoptotic protein groups, the Bax 
and BH3-only families, interactions between the Bcl-2 family proteins control permeabilization 
of the mitochondrial outer membrane (MOM) (Puthalakath 2002). MOMP (mitochondrial outer 
membrane permeabilization) engenders the release of intermembrane space proteins (i.e. 
Cytochrome c), located between the outer (OMM) and inner (IMM) mitochondrial membranes, 
into the cytosol triggering cell death (Chipuk 2006). Functionally, anti-apoptotic proteins 
including Bcl-2 and Bcl-xl inhibit apoptosis, cellular stress sensors BH3 proteins activate 
MOMP, and executioner proteins Bax or Bak permeabilize MOM by oligomerizing (Shamas-Din 
2013). Regulation of the cell-intrinsic death pathway has been linked to the ERK1/2 signaling 
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pathway. Expression of BH3-only protein, Bim is repressed by phosphorylation and proteasome-
dependent degradation mediated under ERK1/2 pathway activation (Weston 2003, Ley 2003).   
 In addition to mediating cell fate, findings implicate ERK1/2 pathway activation of 
playing a role in neuroprotection. Phospho-activation of MEK and ERK inactivates pro-apoptotic 
Bcl-2-associated death protein, BAD, to protect hypoxic neuronal injury in a mouse model (Jin 
2002). Protecting rat cortical neurons from oxidant injury is mediated by ERK activation and 
Bcl-2 induction (Sanchez 2012). MEK/ERK pathway is involved in vascular endothelial growth 
factor (VEGF) protection of cortical neurons against mechanical trauma injury induced apoptosis 
(Ma 2011). 
Stress-inducible HSP70 is a molecular chaperone that assists in cellular protein folding 
processes (Mayer 2005). Associating protective ERK pathway activation with HSP70 protein 
folding, eIF2a protein synthesis, and protein modification activities suggest a possible pathway 
for ATF5 protection. Activation of the MAPK/ERK pathway mediates HSP70 protection against 
oxygen-glucose deprivation injury (Yu 2015). ERK signaling increases HSP70 expression to 
protect against oxidative stress-induced neuronal apoptosis (Qi 2016). Amino acid stress-
activated pathway requires MEK signaling to phosphorylate eIF2a (Thiaville 2008). Cell 
proliferation and survival is reliant on p300-dependent ATF5 acetylation to mediate ERK/MAPK 
activation of transcription factor early growth response factor-1 (Egr-1) gene (Liu 2011). 
Examination of the ERK signaling pathway under PGJ2 stress in our studies allowed elucidation 
of the ATF5 neuroprotective pathway. Results demonstrated ERK activation mediated ATF5 
protection in the presence of PGJ2 toxicity.    
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2.2.  RESULTS 
 
2.2.1.  ERK plays a prosurvival role against PGJ2 toxicity 
The dual role of extracellular signal-regulated kinase (ERK) in neurons has been shown 
to be both anti-apoptotic as well as pro-apoptotic (Li 2014). Exploring ERK under PGJ2 stress 
will elucidate its participation in the mechanism recruited for ATF5 neuroprotection. Proteins 
extracted from PGJ2 treated rat cortical neurons, in the absence or presence of MEK 1/2 inhibitor 
U0126, were analyzed by western blotting. MEK is the upstream kinase that activates 
(phosphorylates) ERK1/2. Probing for pERK revealed significant activation of ERK with PGJ2 
treatment alone (Figure 10A compare lane 1 and 2; Figure 10C). Introducing U0126 to PGJ2 
treated neurons resulted in an immense reduction in ERK activation (Figure 10A compare lane 2 
and 4; Figure 10C). MTS assay results exhibited a more noticeable decrease in cell viability for 
U0126 treated neurons with or without PGJ2 compared to PGJ2 treatment alone (Figure 10B). 
Associating greater ERK activation and lower cell loss with PGJ2 stress conditions proposes an 
anti-apoptotic role for ERK.  									
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Figure 10. ERK plays a prosurvival role against PGJ2 toxicity. (A) E18 cortical neurons 
were incubated for 16hrs in DMEM and treated with and without PGJ2 (10μM) in the presence 
of U0126 (10µM) for 16 h. Lysates were analyzed by western blotting probing with antibodies 
for pERK and Total ERK. Total ERK was probed as a loading control. (B) Cell viability was 
determined using an MTS assay as described in the Materials and Methods section. Results 
represent the percent cell viability relative to the vehicle control + S.E.M. ****P<0.0001 for 
comparisons to Control. ####P<0.0001, ###P<0.001 for comparisons to PGJ2. (C) Blots were 
quantified using ImageJ. ****P<0.0001 for comparisons to Control in DMEM for pERK. 
####P<0.0001 for comparisons to PGJ2 in DMEM for pERK. ++++P<0.0001 for comparisons to 
U0126 in DMEM for pERK.  
C B 
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2.2.2.  ERK regulates apoptosis and oxidative stress 
 To further study the impact ERK protection has against PGJ2 toxicity proteins extracted 
from PGJ2 treated rat cortical neurons in the absence or presence of U0126 were analyzed by 
western blotting. Significant increases of cleaved Caspase-3 and HO-1 activation were detected 
in neurons treated with PGJ2 alone or in combination with U0126 (Figure 11A compare lane 
1,2,3 and 4). Results also identified an upregulation of ATF5 protein levels when cortical 
neurons were treated with PGJ2 or in combination with U0126 (Figure 11A compare lane 1,2,3 
and 4). Lower levels of ATF5, HO-1 and Caspase-3 are observed when ERK activation is 
inhibited in PGJ2 treated cells (Figure 11A compare lane 2 and 4). These results suggest that 
ERK regulates in part apoptosis and oxidative stress induced by PGJ2. The effects of ERK 
inhibition are twofold. ERK regulates cell viability, Caspase-3 activation and HO-1 induction in 
PGJ2 treated cells. Whereas ERK inhibition exacerbates the loss in cell viability induced by 
PGJ2 (Figure 10B), a blockade of ERK activation decreases Caspase-3 activation and HO-1 
induction in PGJ2 treated cells. These findings suggest that reducing apoptosis or oxidative stress 
cannot relieve the loss in cell viability induced by PGJ2 when ERK activation is suppressed. 
Therefore, ERK is essential for maintaining cell viability in PGJ2 treated cells via mechanisms 
independent of Caspase-3 activation and HO-1 induction.  
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Figure 11. ERK regulates apoptosis and oxidative 
stress. (A) E18 cortical neurons were incubated for 
16hrs in DMEM and treated with and without PGJ2 
(10µM) in the presence of U0126 (10µM) for 16 h. 
Lysates were analyzed by western blotting probing 
with antibodies for Caspase-3, HO-1, and ATF5. 
Actin was probed as a loading control. (B,C,D) Blots 
were quantified using ImageJ. ****P<0.0001, *P<0.05  
for comparisons to PGJ2 in DMEM for ATF5. 
###P<0.001, ##P<0.01 for comparisons to U0126 + 
PGJ2 in DMEM for ATF5. ****P<0.0001, ***P<0.001, 
**P<0.01   for comparisons to Control in DMEM for 
Caspase-3 and HO-1. ####P<0.0001, ###P<0.001 
for comparisons to PGJ2 in DMEM for Caspase-3 
and HO-1. ++(P=0.0014) indicates a significant 
difference between U0126 vs. U0126 + PGJ2 in 
DMEM for HO-1. +P<0.05 for comparisons to U0126 
in DMEM for HO-1. 	
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2.2.3.  ERK activation necessary for ATF5 overexpression to restore cell viability against 
PGJ2 toxicity 
 Overexpressing ATF5 in the presence of ERK inhibition will allow additional 
understanding about the protective pathway instituted by ERK under PGJ2 stressed conditions. 
Proteins extracted from PGJ2 treated rat cortical neurons overexpressing ATF5 in the absence or 
presence of U0126 were analyzed by western blotting. Probing for pERK revealed noticeable 
ERK stimulation with PGJ2 treatment alone compared to Control (Figure 12A compare lane 1 
and 2; Figure 12B). However, inhibiting with U0126 significantly decreased the observed PGJ2 
induced ERK activation (Figure 12A compare lane 2 and 4; Figure 12B). Enhancing ATF5 
culminated in a similar pattern of ERK activation (Figure 12A compare lane 5,6,7 and 8; Figure 
12B), although at notably diminished levels. MTS assay results (Figure 12C) illustrate a 
significant increase in cell viability for either U0126 or PGJ2 treated neurons when ATF5 is 
enriched (Figure 12C). In these experiments, overexpression of ATF5 rescues neurons from the 
loss in cell viability induced by PGJ2, or U0126 alone but not PGJ2/U0126. These findings 
reinforce the notion that ERK is required to maintain viability in PGJ2 treated cells.  
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Figure 12. ERK activation necessary for ATF5 overexpression to restore cell viability against 
PGJ2 toxicity. (A) E18 cortical neurons transfected with an ATF5 construct using a magnetofection 
technique as described in the Materials and Methods section were incubated for 16hrs in DMEM and 
treated with and without PGJ2 (10µM) in the presence of U0126 (10µM) for 16 h. Lysates were 
analyzed by western blotting probing with antibodies for pERK and Total ERK. Total ERK was 
probed as a loading control. (B) Blots were quantified using ImageJ. ****P<0.0001 for comparisons to 
PGJ2 in DMEM for pERK. #P<0.05 for comparisons to U0126 + PGJ2 in DMEM for pERK. (C) Cell 
viability was determined using an MTS assay as described in the Materials and Methods section. 
Results represent the percent cell viability relative to the vehicle control + S.E.M. ***P<0.001 for 
comparisons to PGJ2. ####P<0.0001 for comparisons to U0126. 
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2.2.4.  ATF5 expression elicited by ERK mediates survival against PGJ2 toxicity 
independent of oxidative stress and apoptosis induction 
 Examining ATF5 under ERK inhibition will provide insight into the interplay between 
these two components of a prospective neuroprotective regulatory mechanism against PGJ2 
toxicity. Western blots consisting of proteins extracted from PGJ2 treated rat cortical neurons 
overexpressing ATF5 in the absence or presence of U0126 were probed for Caspase-3, HO-1, 
and ATF5. Although an escalation in ATF5 is observed in conjunction with a decrease in cleaved 
Caspase-3 and HO-1 activation in PGJ2 stressed neurons overexpressing ATF5 (Figure 13A 
compare lane 2 and 6), diminished ATF5 levels along with a reduction in Caspase-3 activation 
and HO-1 induction associated with ERK inhibition in PGJ2 treated cells remain unaltered under 
ATF5 enhancement (Figure 13A compare lane 4 and 8.  In these experiments, overexpression of 
ATF5 does not significantly relieve the loss in cell viability in PGJ2/U0126 treated cells (Figure 
12C). Results suggest the protective role of ATF5 is regulated by the presence of ERK managing 
ATF5 protein levels. Besides demonstrating the capability to bring about oxidative stress and 
apoptosis, ERK also exhibits a prosurvival role independent of these inductions. 
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Figure 13. ATF5 expression elicited by 
ERK mediates survival against PGJ2 
toxicity independent of oxidative stress 
and apoptosis induction. (A) E18 cortical 
neurons were incubated for 16hrs in DMEM 
and treated with and without PGJ2 (10µM) in 
the presence of U0126 (10µM) for 16 h. 
Lysates were analyzed by western blotting 
probing with antibodies for Caspase-3, HO-1, 
and ATF5. Actin was probed as a loading 
control. (B,C,D) Blots were quantified using 
ImageJ. ****P<0.0001 for comparisons to 
PGJ2 in DMEM for Caspase-3, HO-1, and 
ATF5. ##P<0.05 for comparisons to Control 
in DMEM for Caspase-3.  	
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2.3.  Discussion 
 	 The extracellular signal-regulated kinase (ERK) signaling cascade plays a role in the 
regulation of neuronal apoptosis (Li 2014). Under amino acid limitation in Hepatoma cells MEK 
signaling phosphorylates eIF2a (Thiaville 2008) to activate the integrated stress-response (ISR), 
a diverse cellular stress response pathway (Pakos-Zebrucka 2016). ERK signaling has been 
shown to increase HSP70 expression to protect against oxidative stress-induced neuronal 
apoptosis (Qi 2016). Additionally, it has been demonstrated in Zebrafish that HSP70 expression 
is dependent on ERK activation (Keller 2008). HSP70 binding contributes to the stability of 
ATF5 by blocking protein degradation to promote survival (Li 2011). Reflective of literature 
suggesting a protective role for ERK, our studies examining the ERK signaling pathway under 
PGJ2 stress elucidated a possible regulatory mechanism mediating ATF5 neuroprotection. Both 
ATF5 protein levels and ERK phosphorylation increased under PGJ2 stress conditions (Figure 
12B and 13C). ATF5 overexpression rescues PGJ2 or U0126 treated cells from a loss in cell 
viability (Figure 12C). However, inhibition of ERK with U0126 in PGJ2 treated cells eliminates 
the recovery in cell viability elicited by the enhancement of ATF5 (Figure 12C). Results 
demonstrate ERK is essential for maintaining cell viability in PGJ2 treated cells. ERK signaling 
cascades have been implicated in maintaining cell viability in glioblastoma via Nrf2, a 
transcription factor NF-E2-related factor 2 that controls adaptive defense responses (Cong 2013), 
and in mouse progenitor B cell line BaF3 following heat shock insult (Ng 2000).   	 Protection exhibited by the overexpression of ATF5 in earlier findings were incapable of 
mitigating the reduction in cell viability from PGJ2 stress when MEK inhibitor U0126 attenuated 
ERK activation (Figure 12C). Previous studies associate the MAPK/ERK pathway with 
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mediating HSP70, a stabilizer of ATF5 in glioma cells (Li 2011). In conditions of ERK 
inhibition a reduction in HSP70 expression would expose ATF5 to degradation. A considerable 
decline in ATF5 protein expression in cells experiencing PGJ2 stress and ERK inhibition (Figure 
13C), even though it was being upregulated, endorses this possibility of ERK having a hand in 
regulating ATF5. 
  A hypothesis proposes chronic neuroinflammation involvement in the pathogenesis of 
neurodegeneration results from the up-regulation of cyclooxygenase COX-2 by prostaglandins 
(Figueiredo-Pereira 2015). Prostaglandins of the J2 series have been shown to induce 
intracellular oxidative stress (Kondo 2001). Moreover, a metabolite of PGJ2, 15d-PGJ2 induces 
mitochondrial-dependent apoptosis in renal proximal epithelial cells (Lee 2009). 15d-PGJ2 
utilizes MAPK activation involving ROS to induce COX-2 expression in human osteosarcoma 
cells (Kitz 2011). Supportive of these existing observations, our results also indicate ERK 
activation induces apoptosis and oxidative stress under PGJ2 toxicity (Figure 13B and D). 
Independent of eliciting oxidative stress and apoptosis, also exhibiting prosurvival capabilities 
illustrate the dual roles played by ERK (Figure 12).   
 Collectively, results from our study implicate ERK as a mediator of ATF5 protection 
against PGJ2 toxicity. The phosphorylation of ERK coinciding with enhanced ATF5 expression 
under PGJ2 stress suggests a mechanistic pathway to stabilize ATF5 in order to induce a 
protective cascade, such as UPRmt.	 		 	
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CHAPTER III 
 
ATF5 mediates cellular respiration to protect against PGJ2 associated 
mitochondrial dysfunction 
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3.1.  Introduction 
 
 The high-energy demands of brain metabolism necessitate consumption of nearly 20% of 
a body’s daily energy resources yet it constitutes only 2% of the body’s mass (Rolfe 1997). As a 
major supplier of ATP, the mitochondrion plays an important role in cellular bioenergetics 
supporting cell function and cell survival/death pathways (Nicholls 2000; Bernardi 1999). 
Mitochondria are double-membrane bound organelles consisting of an outer mitochondrial 
membrane (OMM) containing protein-based pores allowing the passage of small molecules, an 
inner mitochondrial membrane (IMM) composed of proteins involved in electron transport that 
drives oxidative phosphorylation (OXPHOS) to generate ATP, and an intermembrane space 
between the OMM and IMM (The Cell: A Molecular Approach 2nd edition). The process of 
OXPHOS entails protons traveling from protein complexes I, II, III, and IV within the electron 
transport chain that ultimately reduces oxygen to form water and synthesize ATP (Papa 2012).  
Accumulating evidence suggests mitochondrial dysfunction contributes to the 
pathogenesis of neurodegenerative diseases (Schapira 2012; Reddy 2009; Beal 2005). 
Mitochondrial gene expression time-course of aging mice implicates mitochondrial dysfunction, 
oxidative damage, and cytochrome c in age-related neurodegenerative diseases (Manczak 2005). 
Exacerbation of oxidative stress by mitochondrial dysfunction is proposed to contribute causally 
to neurodegenerative pathology (Lin 2006). Robust removal of H2O2 in the brain demonstrates 
ROS detoxifiying capabilities by the mitochondria (Zoccarato 2004). ROS removal system 
failure induces a net ROS production by mitochondria resulting in oxidative stress (Andreyez 
2005). 
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 An essential participant in the pathogenesis of neurodegenerative diseases, ascertaining 
mitochondrial health in cells allows evaluation of its impairment under stress conditions. 
Utilizing the Agilent Seahorse XF Cell Mito Stress Test (CMS) to measure key parameters of 
mitochondrial function enables an assessment. This assay can directly measure cellular oxygen 
consumption rate (OCR) by applying sequential compound injections of oligomycin, carbonyl 
cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP), and a mix of rotenone and antimycin A. 
Calculations utilizing these parameters along with basal respiration will yield data about proton 
leak and spare respiratory capacity (Figure 14). As an inhibitor of ATP synthase (complex V), 
the oligomycin injection will naturally result in the decrease of OCR to demonstrate the level of 
ATP production that comes from mitochondria. Maximum capability of the mitochondria is 
examined with the injection of FCCP, an uncoupling agent that collapses the proton gradient and 
disrupts the mitochondrial membrane potential consequently allowing oxygen consumption by 
complex IV. The final injection combination of rotenone, a complex I inhibitor, and antimycin 
A, a complex III inhibitor disables mitochondrial respiration and facilitates the determination of 
nonmitochondrial respiration executed by processes besides the mitochondria (Figure 15). 
Essentially, serially injected compound oligomycin measures ATP production, FCCP measures 
maximal respiration, and a mix of rotenone and antimycin A measures non-mitochondrial 
respiration.  
Considering the brain depends on glucose as its primary energy source, it is suitable to 
focus on glycolysis as an alternative metabolic pathway to compensate for the energy 
deficiencies associated with mitochondrial dysfunction. Findings suggest neurons have the 
ability to increase glycolysis in response to stimulation (Yellen 2018).  
Mitochondrial dysfunction is associated with an increase of glycolysis in blood cells 
	 40	 
Figure 14. Schematic representation of the Agilent Seahorse XF Mito Stress assay. The 
Agilent SeahorseXFp analyzer measures OCR at basal and after injection of oligomycin, FCCP, 
and antimycin A/rotenone for three measurement cycles at each step. Key parameters of 
mitochondrial function such as basal respiration, ATP production, proton leak, maximal respiration, 
spare respiratory capacity, and nonmitochondrial respiration can be interpreted as shown in the 
figure. Time points of different drug injections are shown with arrows. (Agilent Technologies) 
Figure 15. Complexes of ETC and Target of Action of all compounds in the Seahorse XF 
Cell Mito Stress Test Kit. Oligomycin inhibits ATP synthase (complex V), FCCP uncouples 
oxygen consumption from ATP production, and rotenone and antimycin A inhibits complexes I and 
III, respectively. (Agilent Technologies) 	
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preceding and early Parkinson’s (Smith 2018). Energy contributions attributed to glycolysis can 
be determined by utilizing the Agilent Seahorse XF Glycolytic Rate Assay (GRA). 
Measurements of glycolytic rates for basal conditions and compensatory glycolysis are 
ascertained by inhibiting the mitochondria with rotenone/antimycin A. Administering rotenone 
and antimycin A to inhibit mitochondrial complex I and III, respectively, effectively obstructs 
OXPHOS and stimulates the cell to use glycolysis as a compensatory alternative to satisfy the 
cells’ energy demands. The expulsion of protons, generated during the conversion process of 
glucose to lactose or CO2 to water in the mitochondria, acidifies the extracellular medium. 
Calculating mitochondrial CO2 contribution to extracellular acidification allows for the 
determination of the Proton Efflux Rate (PER), the number of protons exported by cells into the 
assay medium over time, strictly attributed to glycolysis. The injection of 2-deoxy-D-glucose (2-
DG) certifies that the PER generated before its injection is primarily from glycolysis. Glucose 
analog 2-DG inhibits glycolysis through competitive binding to glucose hexokinase, the initial 
enzyme in the glycolytic pathway (Figure 16).  
Employing both Agilent Seahorse Cell Mito Stress Test and Glycolytic Rate Assay in the 
study of ATF5 protection under PGJ2 stress allowed further understanding of the protection 
provided against mitochondrial dysfunction. Associating an ATF5 response with a rise in 
mitochondrial activity and a corresponding reduction in glycolysis suggests protective capability 
against PGJ2 toxicity.                        
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Figure 16. Schematic representation of the Agilent Seahorse XF Glycolytic Rate 
assay.  
The Agilent SeahorseXFp analyzer measures ECAR and OCR at basal and after 
injection of antimycin A/rotenone and 2-deoxy-D-glucose (glucose analog which 
inhibits glycolysis) for three measurement cycles at each step. Key parameters of 
glycolysis such as mitochondrial CO2 contribution to acidification, basal glycolysis, 
and compensatory glycolysis can be interpreted as shown in the figure. Time points of 
different drug injections are shown with arrows. 	
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3.2.  RESULTS 
 
3.2.1. ATF5 regulates mitochondrial respiration in PGJ2 stress conditions 
 Based on findings presented thus far, it has been demonstrated that ATF5 plays a 
neuroprotective role against PGJ2 toxicity. Since mitochondrial stress induces ATFS-1 activation 
of the protective UPRmt pathway in C. elegans, ATF5 was explored as a factor that can protect 
against mitochondrial dysfunction associated with PGJ2 toxicity. Conducting the Agilent 
Seahorse XF Cell Mito Stress (CMS) Test on rat cortical neurons treated with PGJ2 alone, 
U0126 alone, or in combination generated basal oxygen consumption rates (OCR) (Figure 17A) 
for the Control that are consistent with a healthy functioning mitochondria while levels 
decreased approximately 25% from the Control for PGJ2 stressed cells (Figure 17A). Treatment 
with U1026 in the presence or absence of PGJ2 diminished OCR levels even more significantly 
to below 75% of control (Figure 17A). This suggests ERK contributes to mitochondrial function. 
The fact that viability is reduced in PGJ2/U0126 treated cells (Figure 10) may reflect this result. 
Basal levels are indicative of energy demands of a cell where healthy neurons require enormous 
amounts of energy. Following the oligomycin injection, which inhibits complex V, a 
considerable drop in OCR for the Control revealed that the mitochondria contributes 
significantly to the ATP demands of the cell (Figure 17A). As for U0126 or U0126 + PGJ2 
treated neurons, the persistence of low OCR after the oligomycin injection, reflected by low ATP 
production by the mitochondria (Figure 17A), in conjunction with a modest proton leak implies 
low mitochondrial respiration. The examining of basal respiration not attributed to ATP 
production in PGJ2 treated cells, revealed significant proton leak and low ATP contribution from 
respiration suggesting the presence of mitochondrial damage (Figure 17A). Lastly, analyzing the 
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maximum capability of the mitochondria showed OCR increased back to similar baseline levels 
for control cells after the FCCP injection demonstrating mitochondria in control cells are capable 
of responding to greater ATP demands (Figure 17A). Conversely, cortical neurons treated with 
either PGJ2 or U0126 or in combination did not exhibit this increase of OCR after the FCCP 
injection proposing a large portion of respiration maximum was utilized leaving minimal 
reserves available to satisfy higher energy requests. This again suggest that ERK may regulate 
mitochondrial function as mentioned above. 
To understand the impact ATF5 has on mitochondrial function Cell Mito Stress (CMS) 
Test assessments, made by measuring key parameters of mitochondrial function, were performed 
on ATF5 transfected rat cortical neurons treated with PGJ2 alone, U0126 alone, or in 
combination. Basal OCR for Control cells enhancing ATF5 (Figure 17B), albeit at slightly lower 
levels than Controls not overexpressing ATF5 (Figure 17A), along with ATP production levels 
being at least 75% of basal respiration levels demonstrating the mitochondria contributed 
significantly to the ATP demands of Control cells (Figure 17B), indicate a normal functioning 
mitochondria (Figure 17B). Dramatic reduction in basal OCR along with low OCR in ATP 
production and minimal proton leak for ATF5 upregulated cells receiving PGJ2 treatment 
implies minimal mitochondrial respiration activity (Figure 17B). Cortical neurons treated with 
U1026 or a combination of U0126 and PGJ2 displayed an OCR pattern similar to PGJ2 exposed 
cells (Figure 17B), revealing low mitochondrial respiration under these stress conditions while 
overepressing ATF5. Additionally, relatively low spare capacity for all conditions indicate the 
inability of the cell to respond to additional energetic demands (Figure 17B). In the case of 
control cells transfected with ATF5, high basal OCR and ATP production coordinated with low 
proton leak and spare capacity suggest healthy mitochondria are working at their maximum 
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capacities. For ATF5 enhanced cells treated with PGJ2, U0126, or in combination the low basal 
OCR, ATP production, proton leak, and spare capacity indicate mitochondria of distressed cells 
working at their apex are only capable of generating low amounts of ATP (Figure 17B). ATF5 
appears to have an effect on the mitochondrial respiration of transfected Control and PGJ2 
treated cells (Figure 17B) compared to untransfected cells (Figure 17A), proposing a reduction in 
basal OCR minimizes proton leak and enables mitochondria working at maximum capacity to 
satisfy ATP needs, correlating with improved cell viability results (Figure 4E). 
Further exploration of ATF5 capabilities to mediate mitochondrial function was 
accomplished by performing a CMS Test on ATF5 silenced rat cortical neurons treated with 
PGJ2 alone, U0126 alone, or in combination. Results revealed ATF5 silenced controls (Figure 
17C) produced basal OCR, ATP production, proton leak, and spare capacity readings similar to 
those observed in unaltered Controls (Figure 17A). Basal respiration in ATF5 silenced cells is 
representative of healthy mitochondria since the inability to induce protection by ATF5 was 
unnecessary (Figure 17C). Correspondingly, the detection of extremely low OCR in all areas of 
mitochondrial function for silenced cells receiving treatment exhibit an analysis comparable to 
treated cells overexpressing ATF5 (Figure 17B) suggesting an analogous scenario where 
maximizing mitochondria efforts provide meager amounts of ATP to low respiration energy 
demanding cells (Figure 17C). Silencing ATF5 in the presence of unhealthy mitochondria and 
mitochondrial inhibition appears to diminish mitochondrial activity to barely existent levels. 
Overall, investigations conducted with CMS tests unveiled the ability of ATF5 to modulate 
mitochondrial functions to alleviate PGJ2 toxicity by maximizing respiration in healthy 
mitochondria to fulfill energetic demand.  		
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Figure 17. ATF5 regulates mitochondrial respiration in PGJ2 stress conditions.     The 
OCR was measured in (A) E18 cortical neurons incubated for 16hrs in DMEM and treated with 
and without PGJ2 (2.5µM) in the absence or presence of U0126 (2.5µM) for 16 h, (B) E18 
cortical neurons transfected with an ATF5 construct using a magnetofection technique as 
described in the Materials and Methods section were incubated for 16hrs in DMEM and 
treated with and without PGJ2 (2.5µM) in the presence of U0126 (2.5µM) for 16 h, (C) ATF5 
silenced E18 cortical neurons using an siRNA technique described in the Materials and 
Methods section were incubated for 16hrs in DMEM and treated with and without PGJ2 
(2.5µM) in the presence of U0126 (2.5µM) for 16 h. Quantification of the mean OCR shown for 
respiration under basal conditions (basal), basal respiration rate minus the respiration rate 
recorded with oligomycin (ATP Production), Oligomycin response minus rotenone/antimycin A 
response (proton leak), and respiration rate obtained with FCCP minus the basal respiration 
rate (spare capacity). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 for comparisons to Control 
with or without ATF5 overexpression/silencing. ++P<0.01, +++P<0.001, ++++P<0.0001 for 
comparisons to PGJ2 with or without ATF5 overexpression/silencing.  	
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3.2.2.  ATF5 protects against ROS production induced by PGJ2 toxicity  
Studies performed so far show oxidative stress increasing under conditions of PGJ2 
toxicity. Oxidative stress ensues when there is an imbalance between reactive oxygen species 
(ROS) production and the cellular antioxidant response (Ray-2012).  Considering excessive ROS 
is associated with oxidative stress detecting ROS by staining live cortical neurons with Carboxy-
H2DCFCA will allow an assessment of oxidative damage. Fluorescent images illustrate 
significant ROS generation after a16hr treatment with PGJ2 (Figure 18, compare A2 to B2). Also 
affirming earlier findings, diminishing ROS in ATF5 overexpressing cells treated with PGJ2 
demonstrate ATF5 protects against PGJ2 stress (Figure 18, compare B2 and D2). An inverse 
phenomenon of elevated ROS production was observed in ATF5 silenced neurons with or 
without PGJ2 treatment (Figure 18, compare B2, E2, and F2). Created during mitochondrial 
respiration, ROS experiences reductions or escalations depending on ATF5 expression, 
reinforcing the Cell Mitochondrial Stress Test analyses suggesting ATF5 protects against PGJ2 
toxicity by mediating mitochondrial function.    								
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Figure 18. ATF5 protects against ROS production induced by PGJ2 toxicity.            
(A) E18 cortical neurons incubated for 16hrs in DMEM and treated with and without PGJ2 (10µM) for 
16 h, (B) E18 cortical neurons transfected with an ATF5 construct using a magnetofection technique 
as described in the Materials and Methods section that were incubated for 16hrs in DMEM and 
treated with and without PGJ2 (10µM) (C) ATF5 silenced E18 cortical neurons using an siRNA 
technique described in the Materials and Methods section that were incubated for 16hrs in DMEM and 
treated with and without PGJ2 (10µM) for 16 h. Cells were labeled with ROS (green) as described in 
Materials and Methods section. Nuclei were counterstained with DAPI. Data are representative of 
experiments repeated at least three times. 	
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3.2.3.  ATF5 maintains mitochondrial membrane potential against PGJ2 toxicity   
Mitochondrial dysfunction indicated by Cell Mito Stress Tests (Figure 17) coincides with 
HO-1 induction and Caspase-3 cleavage observed under conditions of PGJ2 toxicity (Figure 3). 
Visualizing ROS production further associates mitochondrial impairment with PGJ2 stress 
(Figure 19B2). Evaluating the ΔΨ
m 
of cortical neurons by labeling with TMRE, a positive 
charged dye retained in healthy mitochondria due to high ΔΨ
m
, revealed increased episodes of 
ΔΨ
m  
collapse with PGJ2 treatment (Figure 19A, compare A2 and B2). By overexpressing ATF5, 
the depletion of ΔΨ
m 
associated with PGJ2 toxicity is reduced (Figure 19B, compare B2 and C2). 
In contrast, silencing ATF5 achieves the opposite effect, an increase in dissipating ΔΨ
m 
under 
PGJ2 stress conditions is observed (Figure 19C, compare B2 and F2). Improving TMRE 
retention in PGJ2 treated cells by elevating ATF5 expression demonstrates ATF5 restoration of 
mitochondrial health combats PGJ2 toxicity.  
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Figure 19. ATF5 maintains mitochondrial membrane potential against PGJ2 toxicity. 
(A) E18 cortical neurons incubated for 16hrs in DMEM and treated with and without PGJ2 (10µM) for 
16 h, (B) E18 cortical neurons transfected with an ATF5 construct using a magnetofection technique 
as described in the Materials and Methods section that were incubated for 16hrs in DMEM and 
treated with and without PGJ2 (10µM) (C) ATF5 silenced E18 cortical neurons using an siRNA 
technique described in the Materials and Methods section that were incubated for 16hrs in DMEM and 
treated with and without PGJ2 (10µM) for 16 h. Cells were labeled with TMRE (green) as described in 
Materials and Methods section. Nuclei were counterstained with DAPI. Data are representative of 
experiments repeated at least three times. 	
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3.2.4.  Glycolysis contribution maintained under PGJ2 stress  
Considering mitochondrial respiration is a major source of energy for neurons,	 severe 
mitochondrial impairment induced by PGJ2 resulted in only a moderate 20% loss of cell 
viability. Cell recovery achievement by ATF5 optimizing mitochondrial function inadequately 
satisfies the energy demand needed for accomplishing the restoration observed. Probing for an 
alternative energy source to compensate for mitochondrial dysfunction energy limitations 
prompted the usage of the Agilent Seahorse XF Glycolytic Rate Assay (GRA) to measure 
glycolysis. Performing the GRA Test on rat cortical neurons untreated and treated with PGJ2 
alone, U0126 alone, or in combination generated similar basal levels (Figure 20A) for all 
conditions. Lower compensatory levels compared to Control indicated cells treated with PGJ2, 
U0126 or in combination engaged glycolysis to a higher extent (Figure 20A). This escalation, 
detected under treatment conditions, implies glycolysis may be compensating for the reduction 
observed in mitochondrial respiration (Figure 17A). Moreover, these results suggest inhibiting 
ERK regulation of mitochondrial function (Figure 17A) influences a cell’s glycolytic 
expenditure similarly to that exhibited under mitochondrial dysfunction induced by PGJ2 stress. 
Both Cortical neurons with enhanced ATF5 expression (Figure 20B) and cells experiencing 
ATF5 silencing (Figure 20C) illustrated deficits in basal and compensatory levels compared to 
untransfected cells for all treated and untreated circumstances (Figure 20A). Mimicking the basal 
and compensatory pattern of untransfected cells (Figure 20A) also depicts higher glycolytic 
activity for upregulated and silenced cells receiving treatment (Figure 20B and 20C). Increasing 
glycolysis may have contributed to improvements observed in the cell viability of PGJ2 treated 
cells upregulating ATF5 (Figure 4). However, under ERK inhibition the overexpression of ATF5 
does not appear to enhance glycolysis compensation in a manner that relieves the loss in cell 
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viability (Figure 12) induced by PGJ2 stress. In comparing the contribution glycolysis and 
mitochondrial respiration supplies to fulfill the energetic demands of neurons, glycolysis appears 
to maintain the same contribution percentage pattern across treatments between untransfected 
and ATF5 upregulated or silenced cells (Figure 20D). Decreases in respiration OCR and 
glycolysis, observed under circumstances of ATF5 overexpression or silencing, leads to the 
speculation that glycolytic activity adjusts to ATF5 modulations of mitochondrial function. The 
ability for cell loss recovery by healthy cells overexpressing ATF5 compared to exhibiting an 
escalation of cell loss in distressed ATF5 silenced cells in which both glycolysis and 
mitochondrial respiration is maximized in a lower cellular energetic demand environment 
suggests mitochondrial respiration efficacy as a conduit for the more favorable outcome of 
higher cell viability in PGJ2 stressed cells experiencing elevated ATF5 expression.						
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Figure 20. Glycolysis contribution maintained under PGJ2 stress. The OCR and ECAR 
was measured in (A) E18 cortical neurons incubated for 16hrs in DMEM and treated with and 
without PGJ2 (2.5µM) in the absence or presence of U0126 (2.5µM) for 16 h, (B) E18 cortical 
neurons transfected with an ATF5 construct using a magnetofection technique as described in 
the Materials and Methods section were incubated for 16hrs in DMEM and treated with and 
without PGJ2 (2.5µM) in the presence of U0126 (2.5µM) for 16 h, (C) ATF5 silenced E18 
cortical neurons using an siRNA technique described in the Materials and Methods section 
were incubated for 16hrs in DMEM and treated with and without PGJ2 (2.5µM) in the 
presence of U0126 (2.5µM) for 16 h. Quantification of the mean glycoPER shown for 
glycolysis under basal conditions (Total ECAR – Mitochondrial-derived CO2 contribution to 
acidification), rotenone/antimycin A response minus basal glycolysis (compensatory 
glycolysis), and % basal glycolysis/Total ECARrespiration (% PER from glycolysis). *P<0.05, 
**P<0.01, ***P<0.001, and ****P<0.0001 for comparisons to Control.  	
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3.3.  Discussion 
 
 As a major supplier of ATP, the mitochondrion plays an important role in cellular 
bioenergetics supporting cell function and cell survival/death pathways (Nicholls 2000; Bernardi 
1999). An essential participant in the pathogenesis of neurodegenerative diseases, ascertaining 
mitochondrial health in cells allows an evaluation of its impairment under stress conditions. In 
our studies, we demonstrate ATF5 has the ability to mediate cellular respiration to protect 
against PGJ2 induced mitochondrial dysfunction. 
 Results from CMS assays suggest ATF5 protection against PGJ2 toxicity involves 
modulating mitochondrial functions. Expectedly, an increase in basal respiration and ATP 
production would indicate improved mitochondrial health, as observed in Control cells (Figure 
17A). Overexpressing ATF5 produced lower basal OCR and proton leak in PGJ2 treated cells 
(Figure 17B) demonstrating a reduction in respiration diminishes the presence of damage. 
Focusing on altering respiration as a way to minimize proton leak would enhance cell viability 
(Figure 4D) and enable improvements in efficacy. Furthermore, the significant decline in basal 
OCR together with employing respiration maximum (Figure 17A) and exhibiting a reduction in 
cell viability (Figure 10) under U0126 treatment suggest ERK regulates mitochondrial function. 
Comparisons between cell viability and CMS test results illustrated the larger impact observed in 
cell viability was not reflected in CMS tests. Although the tetrazolium salt used in cell viability 
assays measure mitochondrial metabolic rate, mitochondria are not the sole source of MTS 
reduction. Additional sources outside of the mitochondria contributing to MTS reduction might 
explain why CMS tests do not demonstrate greater significance in mitochondrial respiration 
between control and treated neurons. Another explanation for the disparity observed in the two 
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assays may result from not normalizing the CMS test results to cell viability at the completion of 
the assay. By normalizing to cell viability, comparisons between treated and control conditions 
might yield a data pattern with greater significance.      
 ATF5 protection against PGJ2 induced ROS and loss of membrane potential (Figure 15 
and16) demonstrates mitochondrial impairment is associated with PGJ2 toxicity. These results 
coincide with the previous analysis conducted on mitochondrial function indicating ATF5 
protection against PGJ2 stress targets respiration to re-establish mitochondrial health in an 
attempt to recover cell viability. 
The Pasteur Effect and Crabtree Effect both describe the phenomenon where increasing 
either oxygen availability or glucose consumption, respectively, will result in the reduction of the 
other metabolic pathway (Swerdlow 2013). Findings suggest neurons have the ability to increase 
glycolysis in response to stimulation (Yellen 2018). A reciprocal glycolysis-respiration 
relationship exists under conditions of fixed energy demand (Swerdlow 2013). We demonstrate 
in our studies of glycolysis the existence of a compensatory relationship between glycolysis and 
mitochondrial respiration. Engaging glycolysis more extensively (Figure 20) appears to 
compensate for the reduction in mitochondrial respiration (Figure 17) exhibited by treated cells. 
While increasing glycolysis under ATF5 overexpression improves cell viability in PGJ2 treated 
cells (Figure 12), it does not relieve the loss in cell viability experienced by PGJ2 stressed cells 
inhibiting ERK (Figure 12). Comparing the contributions made by glycolysis vs respiration 
towards cellular energetic demands (Figure 20D) revealed maintaining the balance between the 
ATP generating pathways in varying ATF5 expression conditions involved modulating overall 
energy requirements. For treated cells upregulating or silencing ATF5 observing a decline in 
glycolysis (Figure 20B and 20C) complemented similar adjustments illustrated in mitochondrial 
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respiration (Figure 17B and 17C), thus preserving the balance with a universal reduction in 
cellular ATP needs.  
Taken together, ATF5 protects against PGJ2 induced mitochondrial dysfunction by 
reducing ROS, loss of membrane potential, and mitochondrial damage. Low basal OCR 
accompanied by a decline in mitochondrial damage in PGJ2 treated neurons overexpressing 
ATF5 suggests modulating mitochondrial functions as a protective mechanism. Attempts at 
improving mitochondrial efficacy decreased both mitochondrial respiration and glycolysis 
demonstrating a reciprocal glycolysis-respiration relationship entails maintaining metabolic 
pathway balance. The improvement in cell viability in PGJ2 or U0126 treated cells upregulating 
ATF5 occurs under the depreciation of both mitochondrial respiration and glycolysis, however 
this restoration in PGJ2 stressed cells is impaired by the inhibition ERK regulating mitochondrial 
function. 				  
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Overall, our present study demonstrates multiple layers are involved in the regulatory 
mechanism mediating ATF5 protection against PGJ2 induced toxicity in rat cortical neurons. 
ATF5 protects primary cortical neurons against mitochondrial dysfunction associated 
with PGJ2 inflammation by reducing apoptotic activator Caspase-3 and oxidative stress indicator 
HO-1. Further demonstrating its capacity to alleviate oxidative damage, ATF5 upregulation 
diminished the dissipation of mitochondrial membrane potential and ROS production. Analogous 
to ATFS-1 studies, illustrating ATF5 expression in PGJ2 stressed cortical neurons suggests 
mRNA transcript stabilization elicits accumulation as well as trafficking between the 
mitochondria and nucleus supporting the possibility of UPRmt induction, thereby activating 
mitochondrial protective genes in order to re-establish protein homeostasis. Assessing the 
oxygen consumption rate of cortical neurons revealed ATF5 possesses the capability to modulate 
mitochondrial respiration in an effort to improve mitochondrial health, consequently promoting 
survival against PGJ2 stress. The escalation in glycolysis, exhibited by PGJ2 stressed cells 
overexpressing ATF5, coinciding with the reduction in mitochondrial respiration suggests 
glycolysis contributes to the recovery of cell viability. Additionally, while ERK activation in the 
presence of PGJ2 stress propagates HO-1 and Caspase-3, it also portrays a prosurvival role 
independent of these inductions through the regulation of ATF5 and mitochondrial function.  
In conclusion, the mediation of ATF5 neuroprotection against PGJ2 toxicity entails a 
coordinated effort by a multitude of regulatory mechanisms that recover mitochondrial 
functionality, essential for high energy-using neurons. Mitochondrial restorative pathways 
provide an avenue of exploration for therapeutic treatments targeting neurodegenerative 
disorders. 
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Figure 21. Model of ATF5 neuroprotection against PGJ2 induced toxicity. ATF5 
protects against PGJ2 induced stress by reducing Caspase-3 cleavage, HO-1 induction, 
ROS production, and the loss of ΔΨ
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5.1 Materials – Prostanglandins J2 analog CAY10410 from Cayman Chemical (Ann Harbor, 
MI). The inhibitor of MEK1/2 (U0126) was obtained from Promega Corporation (Madison, WI). 
Primary Antibodies: Caspase-3 (Cell Signaling Technologies, Danvers, MA, USA), HO-1 (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), Actin (Sigma, St. Louis, MO), pERK (Cell 
Signaling Technologies, Danvers, MA, USA), Total ERK (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), a-tubulin (Calbiochem, San Diego, CA, USA), ATF5 (a generous gift 
provided by Dr. Cole Haynes’ Lab, University of Massachusetts Medical Center, Worchester, 
MA; produced according to Zhou, Palam et al 2008).   	
5.2 Cell Cultures – Primary cerebral cortical cultures: Dissociated cultures from Sprague 
Dawley rat embryonic (E18, both sexes) cerebral cortical neurons were prepared as follows. The 
isolated cortices free of meninges were digested with papain (0.5 mg/ml from Worthington 
biochemical) in Hibernate E without calcium (BrainBits LLC) at 370C for 30 min in a humidified 
atmosphere containing 5% CO2. After removal of the enzymatic solution, the tissues were gently 
dissociated in Neurobasal (NB) medium (Invitrogen). Dissociated tissues were centrifuged at 300 
x g for 2 min. The pellet was resuspended in Neurobasal medium without antibiotics and plated 
on 10-cm dishes precoated with 50 µg/ml poly-D-lysine (Sigma). Cells were plated at a density 
of 6 x 106 cells/10-cm dish. Cultures were maintained in Neurobasal medium supplemented with 
B27 and L-GlutaMAX (all from Invitrogen) at 370C in a humidified atmosphere containing 5% 
CO2. Half of the medium was changed every 4 days. Experiments were performed at 7 DIV.  
 
5.3 Culture treatments – On DIV 7, cells were changed to DMEM supplemented with L-
GlutaMAX and sodium pyruvate (all from invitrogen) in the absence of serum, and incubated for 
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16 hr prior to harvest for western blotting or subject to cell viability assay, ROS and TMRE 
detection. All treatments were added during this 16 hr period as follows when applicable: PGJ2 
(10 µM) and U0126 (10 µM) were treated for 16 hr. DMSO was used as vehicle control.   	
5.4 Protein Extraction and Western Blotting - After treatment, cells were rinsed with PBS and 
harvested in a lysis buffer as described previously (Rockwell et al. 2004). Protein concentrations 
were determined using a bicinchoninic acid assay (BCA) according to manufacturer’s 
instructions (Pierce, Rockford, IL). Equal amounts of protein (30	µg) were resolved by SDS-
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Blots were then 
blocked and incubated overnight at 40C with the following primary antibodies: HO-1 and 
ERK1/2 from Santa Cruz; Caspase-3 and pERK from Cell Signaling. Actin (Sigma-Aldrich) was 
used as a loading control. Immunoreactive bands were detected with corresponding anti-mouse 
and anti-rabbit secondary antibodies conjugated to horseradish peroxidase and visualized with 
the SuperSignal West Pico Chemiluminescent Substrate (Pierce Endogen, Rockford, IL). Data 
were quantified using ImageJ from NIH.		
5.5 Cell Viability – Neurons were plated in pre-coated 96-well microtiter plates (2x104 
cells/well) and maintained Neurobasal medium supplemented with B27 and L-GlutaMAX. On 
DIV 7, cells were changed into DMEM as indicated for 16 hr prior to MTS assay. Prior to MTS 
assay measurement, all treatments were performed as follows when applicable: PGJ2 (10	µM) 
and U0126 (10 µM) were treated for 16 hr. On Div 8, cell viability was determined using 
colorimetric MTS assay (Promega Corp, Madison, WI) and quantified according to 
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manufacturer’s instruction. Survival measurements are expressed as the percent of the untreated 
control.	
 
5.6 Oxidative Stress – ROS was measured using the fluorescent dye Carboxy-H2-DCFCA 
(Invitrogen) following the manufacturer’s instruction. Briefly, neurons plated on precoated 8-
well chamber slides were incubated in DMEM for 16 hr prior to adding H2-DCFCA. All 
treatments were performed as follows during this 16 hr if applicable: PGJ2 (10	µM) and U0126 
(10	 µM) were treated for 16 hr. THBP (100 µM) was used to induce ROS production as a 
positive control for 90 min. On DIV 8, 16 hr after in DMEM cells were incubated with 25 µM 
H2-DCFCA following the manufacturer’s instructions and images were immediately taken using 
a Nikon Eclipse TE200 inverted epifluorescence scope. Data are representative of experiments 
that were repeated at least three times. 		
5.7 Mitochondrial Membrane Potential – Loss of mitochondrial membrane potential was 
assessed in living cells labeled with the fluorescent lipophilic cationic dye tetramethylrhodamine, 
ethyl ester (TMRE) (abcam). This dye incorporates into mitochondria with an intact 
transmembrane potential and its release serves as an indicator of a loss in inner membrane 
potential. Neurons plated on 8-well chamber slides were incubated in DMEM for 16 hr prior to 
adding TMRE. All treatments were performed as follows during this 16 hr if applicable: PGJ2 
(10	µM) and U0126 (10 µM) were treated for 16 hr. FCCP (20	µM) was used for 30 min to 
disrupt the mitochondrial membrane potential as a positive control. On DIV 8, 16 hr after being 
in DMEM, neurons were incubated with 200 nM TMRE for 30 min at 370C, then washed with 
fresh medium. Fluorescence images were immediately taken using a Nikon Eclipse TE200 
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inverted epifluorescence scope. Data are representative of experiments that were repeated at least 
three times.					
5.8 RNA Interference – On DIV 7, cultured neurons were transfected with 25nM of Atf5 
SMARTpool® siRNA duplexes (Dharmacon RNA Technologies, Lafayette, CO) using 
Dharmafect Transfection Reagents. After 32 hr, cells were changed to fresh DMEM for 16hrs. 
All treatments were performed as follows during this 16 hr if applicable: PGJ2 (10	µM) and 
U0126 (10 µM) were treated for 16 hr.	
 
5.9 Transfection with magnetofection – On DIV 7, cultures were transfected by 
magnetofection using NeuroMag (Oz Biosciences) on a magnetic plate for 30 min at 37OC using 
a ratio of 1µg of plasmid DNA to 2ul NeuroMag according to manufacturer’s instructions. After 
32 hr, cells were changed to fresh DMEM for 16hrs. All treatments were performed as follows 
during this 16 hr if applicable: PGJ2 (10	 µM) and U0126 (10 µM) were treated for 16 hr. 
pCMVATF5 plasmid (a generous gift provided by Dr. Cole Haynes’ Lab, University of 
Massachusetts Medical Center, Worchester, MA)    
 
5.10 RT-PCR analysis – Total RNA was isolated from rat E18 cortical neurons with the 
RNeasy® Mini Kit (Qiagen). Quantitative RT-PCR (qRT-PCR): Total RNA (1µg) was reverse 
transcribed to cDNA with the All-in-oneTM First-Strand cDNA Synthesis Kit (GeneCopoeia). 
The quantitative analysis of the cDNAs were performed using the All-in-OneTM qPCR Mix Kit 
(GeneCopoeia) in an Applied Biosystems ViiA 7 real-time PCR system with cycling parameters 
of 95OC for 10 min, 95OC for 10 sec, 58OC for 45 sec, and 72OC for 35 sec for 50 cycles. 
	 68	
Primer sequences used for qRT-PCR were rat-atf5-1: forward GTA	TAA	GGC	ACG	AAG	CCA	GA 
and reverse AGC	TTG	GTT	CTC	AGT	TGC	AC; rat-atf5-2: forward AGA	GGG	CAG	AGT	CAG	TGG	AA and reverse GGA	 AGT	 GAA	 ATG	 GAG	 GGA	 CA; GAPDH: forward 
CTTCTGTCTTGATGTTTGTCAACC and reverse ATGGTGAAGGTCGGTGTGAACG. 
 
5.11 Cell Fractionation – To check the subcellular localization of ATF5, treated cells were 
separated to cytosol, mitochondria, and nucleus with cell fractionation kit (Abcam, ab1097919) 
following manufacturer’s instructions, except 2x Buffer A was used in 50% of volume 
recommended.  
 
5.12 Respiration Analysis – Oxygen consumption rate (OCR) and extra acidification rate 
(ECAR) were measured using Seahorse XFp Extracellular Flux Analyzer (Seahorse 
Biosciences). Mitochondrial respiration assays were performed using a Seahorse XFp Cell Mito 
Stress Test Kit and cellular glycolysis was measured using a Seahorse XFp Glycolytic Rate 
Assay Kit, in accordance with manufacturer’s instructions. Briefly, primary cortical neurons 
were seeded at 40,000 cells per well in 8-well Seahorse cell culture miniplates. Following 
treatments, on DIV 8 or 9 culture media in each well was replaced with Seahorse assay media 
and incubated at 37OC in an incubator w/o CO2 for 1 hr. Then the plates were subjected to 
analysis using 1 µM oligomycin, 500 nM FCCP, and 500 nM rotenone/antimycin for Cell Mito 
Stress Test Kit or 500 nM rotenone/antimycin and 50 mM 2-deoxy-D-glucose (2-DG) for 
Glycolytic Rate Assay kit as indicated. The Seahorse assays were analyzed using XFp Wave 
software, according to manufacturer’s instructions.   
 
	 69	
5.13 Statistical Analysis- Data are expressed as the mean + SEM of experiments, all of which 
were replicated at least three times. Statistical significance was assessed by a one-way ANOVA 
(Tukey or Bonferroni analysis) with the Prism 7 program. A difference resulting in P<0.05 is 
considered significant. 	
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CHAPTER VI 
 
FUTURE DIRECTIONS 		
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6.1 Does the overexpression of ATF5 modulate the expression of mitochondrial protective 
genes? 
 
 Techniques such as reverse transcription polymerase chain reaction (RT-PCR) and 
microarray analysis can be utilized to identify which, if any mitochondrial protective genes are 
expressed when ATF5 is upregulated. Activation of the UPRmt has been associated with 
increased transcriptions of HSP60, mtHSP70, and LONP1. Their inductions would indicate 
attempts at re-establishing protein homeostasis. The effect of ATF5 on mitochondrial gene 
expression will be determined using Mouse Mitochondria PCR array (Qiagen) which profiles the 
expression of genes for mitochondrial biogenesis, energy production and function with controls 
by quantitative PCR. These results will show whether ATF5 mimics ATFS-1 in protecting 
against mitochondrial impairment by distinguishing genes upregulated in an ATFS-1 dependent 
manner.  
 
 
6.2 Does the silencing ATF5 induce a Caspase independent cell death in cortical neurons? 
  
PGJ2 treatment induces cell death accompanied by an increase in Capase-3 cleavage. 
ATF5 silencing exacerbates cell viability but not Caspase-3 cleavage. To investigate further if 
both events are caspase-dependent, neurons receiving PGJ2 will be treated with the general 
Caspase inhibitor z-VAD-fmk in the absence or presence of ATF5. Cell viability will be 
measured. A continued presence of cell loss would indicate another method of cell death, besides 
caspase-dependent, is associated with PGJ2 toxicity. Considering autophagy is also a possibility, 
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monitoring LC3-I conversion to LC3-II by immunoblotting would allow an assessment of this 
scenario. An increased amount of LC3-II reflects increased autophagosome formation as a result 
of autophagy induction.        			
6.3 Does ATF5 trafficking to the nucleus in PGJ2 stressed conditions mediate protection?  
  
 The ability of ATF5 to localize to both the mitochondria and the nucleus is due to 
possessing an N-terminal MTS region and a nuclear localization signal (NLS) in the leucine-
zipper domain. Transfecting a pCMVATF5 plasmid without the NLS, preventing ATF5 
localization to the nucleus of cortical neurons, would allow insight into protection mediated by 
nuclear trafficking. If protection against PGJ2 is maintained without the NLS present, then 
nuclear trafficking would be shown not to mediate protection. However, loss of ATF5 protection 
indicated by increased Caspase-3, HO-1, ROS induction, along with cell loss would show 
nuclear trafficking mediates protection. 	
 
6.4 Does ATF5 activate the UPRmt in PGJ2 stressed cortical neurons?  
 
 Induction of the mitochondrial chaperone hsp-60 promoter is associated with activation 
of the UPRmt. To investigate whether PGJ2 stress in cortical neurons induces the UPRmt, a GFP 
reporter containing the hsp-60 promoter would be generated and introduced to cortical neurons. 
Viewing cultures under a fluorescence microscope would allow detection of hsp-60pr::gfp 
expression. Activation of hsp-60pr::gfp in a PGJ2 stress environment by cells overexpressing 
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ATF5 would illustrate ATF5 induces the UPRmt. The lack of hsp-60pr::gfp expression would 
instead indicate ATF5 does not activate the UPRmt.  
 
6.5 How to achieve a more statistically accurate result of ROS production? 
 
 The method used to illustrate the presence of ROS in this work was not statistically 
analyzed. In order to accomplish that flow cytometry would be applied so that dead cells can be 
distinguished from live cells. Since ROS is generated in both dead and live cells, being able to 
distinguish the ROS in only live cells would enable an accurate assessment of PGJ2 toxicity vs a 
normal course of cell death that occurs in a culture of cells. The use of CellROX Green Flow 
Cytometry Assay Kit to bind DNA will exhibit a strong fluorogenic signal upon oxidation that 
remains localized to the nucleus and cytoplasm. When used together with SYTOX red dead cell 
stain, ROS production strictly by live cells can be identified by flow cytometry.   
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